Eli Lilly released positive late-stage trial results demonstrating long-term weight loss maintenance after switching from high-dose injectable GLP-1 therapies.
The studies, published in The Lancet and Nature Medicine, tracked patients who previously lost weight on drugs like Zepbound or Wegovy.
Participants maintained most of their weight loss by transitioning to Lilly’s daily oral pill, Foundayo (orforglipron), or a lower maintenance dose of Zepbound.
This data addresses the clinical challenge of weight regain by providing more convenient and sustainable long-term treatment options.
Analysts believe these results strengthen Lilly’s position in the obesity market by supporting the durability of its blockbuster treatments against competitors.